Immunotherapy combo shows promise in shrinking lung tumors before surgery

NCT ID NCT05925530

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or borderline removable. After initial treatment, some will have surgery followed by more durvalumab, while others will get chemoradiation followed by durvalumab. The main goal is to see how many people can successfully have their tumors surgically removed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug) plus platinum-based chemotherapy
What this could lead to: If successful, this approach could improve the chances of completely removing lung cancer tumors and help keep the cancer from coming back.
What could go wrong: This is a mid-stage trial with only 142 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of the lungs or other organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

The Bronx, New York, 10467, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Charlottesville, Virginia, 22908, United States
Research Site

Vienna, 1130, Austria
Research Site

Vienna, 1140, Austria
Research Site

Kingston, Ontario, K7L 2V7, Canada
Research Site

Chicoutimi, Quebec, G7H 5H6, Canada
Research Site

Montreal, Quebec, H4A 3J1, Canada
Research Site

Brno, 625 00, Czechia
Research Site

Olomouc, 77900, Czechia
Research Site

Prague, 12808, Czechia
Research Site

Prague, 150 06, Czechia
Research Site

La Tronche, 38700, France
Research Site

Marseille, 13008, France
Research Site

Montpellier, 34295, France
Research Site

Mulhouse, 68070, France
Research Site

Paris, 75005, France
Research Site

Pessac, 33604, France
Research Site

Poitiers, 86000, France
Research Site

Toulouse, 31059, France
Research Site

Berlin, 13125, Germany
Research Site

Cologne, 51109, Germany
Research Site

Großhansdorf, 22927, Germany
Research Site

Moers, 47441, Germany
Research Site

Würzburg, 97074, Germany
Research Site

Budapest, 1122, Hungary
Research Site

Törökbálint, 2045, Hungary
Research Site

Bari, 70124, Italy
Research Site

Bologna, 40138, Italy
Research Site

Milan, 20132, Italy
Research Site

Milan, 20133, Italy
Research Site

Milan, 20141, Italy
Research Site

Naples, 80131, Italy
Research Site

Palermo, 90127, Italy
Research Site

Pavia, 27100, Italy
Research Site

Peschiera del Garda, 37019, Italy
Research Site

Lisbon, 1350-352, Portugal
Research Site

Lisbon, 1500-650, Portugal
Research Site

Barakaldo, 48903, Spain
Research Site

Barcelona, 08025, Spain
Research Site

L'Hospitalet de Llobregat, 08908, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28027, Spain
Research Site

Madrid, 28046, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Valencia, 46009, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Solna, 171 64, Sweden
Research Site

Uppsala, SE-751 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.